Lindbrook Capital, LLC Kodiak Sciences Inc. Transaction History

Lindbrook Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 28, 2023	BUY	$4.3 - $9.48 $731 - $1,611	170 Added 395.35%	213 $1,000
Q1 2023 Apr 26, 2023	SELL	$4.81 - $8.88 $346 - $639	-72 Reduced 62.61%	43 $0
Q4 2022 Jan 24, 2023	BUY	$6.52 - $8.05 $326 - $402	50 Added 76.92%	115 $0
Q3 2022 Nov 10, 2022	SELL	$7.57 - $12.5 $196 - $325	-26 Reduced 28.57%	65 $1,000
Q2 2022 Aug 01, 2022	SELL	$5.04 - $9.48 $720 - $1,355	-143 Reduced 61.11%	91 $1,000
Q1 2022 Apr 21, 2022	SELL	$7.09 - $89.45 $2,346 - $29,607	-331 Reduced 58.58%	234 $2,000
Q4 2021 Jan 18, 2022	BUY	$80.85 - $128.49 $43,659 - $69,384	540 Added 2160.0%	565 $48,000
Q3 2021 Nov 05, 2021	BUY	$81.97 - $106.94 $2,049 - $2,673	25 New	25 $2,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $455M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.